Early Detection and Biomarkers in Pancreatic Cancer

Authors:
David E. Misek From the Departments of Surgery, Chemistry, Pathology, and Physiology, University of Michigan Medical School, Ann Arbor, Michigan.

Search for other papers by David E. Misek in
Current site
Google Scholar
PubMed Close
 PhD
,
Tasneem H. Patwa From the Departments of Surgery, Chemistry, Pathology, and Physiology, University of Michigan Medical School, Ann Arbor, Michigan.

Search for other papers by Tasneem H. Patwa in
Current site
Google Scholar
PubMed Close
,
David M. Lubman From the Departments of Surgery, Chemistry, Pathology, and Physiology, University of Michigan Medical School, Ann Arbor, Michigan.
From the Departments of Surgery, Chemistry, Pathology, and Physiology, University of Michigan Medical School, Ann Arbor, Michigan.
From the Departments of Surgery, Chemistry, Pathology, and Physiology, University of Michigan Medical School, Ann Arbor, Michigan.

Search for other papers by David M. Lubman in
Current site
Google Scholar
PubMed Close
 PhD
, and
Diane M. Simeone From the Departments of Surgery, Chemistry, Pathology, and Physiology, University of Michigan Medical School, Ann Arbor, Michigan.
From the Departments of Surgery, Chemistry, Pathology, and Physiology, University of Michigan Medical School, Ann Arbor, Michigan.

Search for other papers by Diane M. Simeone in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 5: Issue 10
Online Publication Date:
Nov 2007
DOI:
https://doi.org/10.6004/jnccn.2007.0086
Full access

Major advances in cancer control will be greatly aided by early detection for diagnosing and treating cancer in its preinvasive state before metastasis. Unfortunately, for pancreatic ductal adenocarcinoma (PDAC), which is the fourth leading cause of cancer-related death in the United States, effective early detection and screening are currently not available and tumors are typically diagnosed at a late stage, frequently after metastasis. Partly because of low sensitivity/specificity, existing biomarkers such as CA19-9 are not adequate as early detection markers of pancreatic cancer. Thus, a great need exists for new biomarkers for pancreatic cancer. This article focuses on recent developments in the identification of new serum protein biomarkers that are useful in the early detection of PDAC.

Correspondence: Diane M. Simeone, MD, Department of Surgery, University of Michigan Medical Center, 1500 East Medical Center Drive, Room TC 2922D, Ann Arbor, MI 48109-0331. E-mail: simeone@umich.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.

  • 2.

    Mann DV, Edwards R, Ho S et al.. Elevated tumour marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474–479.

  • 3.

    Ferrone CR, Finkelstein DM, Thayer SP et al.. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897–2902.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Duffy MJ. CA19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364–370.

  • 5.

    Nazli O, Bozdag AD, Tansug T et al.. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000;47:1750–1752.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Boeck S, Stieber P, Holdenrieder S et al.. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255–264.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Allison DC, Piantadosi S, Hruban RH et al.. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151–159.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Ujiki MB, Talamonti MS. Surgical management of pancreatic cancer. Semin Radiation Oncol 2005;15:218–225.

  • 9.

    Lawrence TS, Blackstock AW, McGinn CJ. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiation Oncol 2003;13:13–21.

  • 10.

    McGinn CJ, Zalupski MM, Shureiqi I et al.. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202–4208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Goldhirsch A, Colleoni M, Domenighetti G et al.. Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol 2003;14:1212–1214.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Lieberman D. How to screen for colon cancer. Annu Rev Med 1998;49:163–172.

  • 13.

    Ferguson JA. Early detection of unsuspected colon cancers in asymptomatic people. Dis Colon Rectum 1993;36:411.

  • 14.

    Mandel JB, Church JH, Snover TR et al.. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365–1371.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Catalona WJ. Management of cancer of the prostate. N Engl J Med 1995;331:996–1004.

  • 16.

    Jacobsen SJ, Katusic SK, Bergstralh EJ et al.. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274:1445–1449.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Lynge E. Screening for cancer of the cervix uteri. World J Surg 1989;13:71–78.

  • 18.

    Brichory FM, Misek DE, Yim AM et al.. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001;98:9824–9829.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Le Naour F, Misek D, Krause M et al.. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001;7:3328–3335.

  • 20.

    Gure AO, Altorki NK, Stockert E et al.. Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res 1998;58:1034–1041.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Stockert E, Jager E, Chen YT et al.. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349–1354.

  • 22.

    Ben-Mahrez K, Sorokine I, Thierry D et al.. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990;46:35–38.

  • 23.

    Pupa SM, Menard S, Andreola S et al.. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993;53:5864–5866.

  • 24.

    Winter SF, Minna JD, Johnson BE et al.. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168–4174.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Raedle J, Oremek G, Welker M et al.. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996;13:241–246.

  • 26.

    Hamanaka Y, Suehiro Y, Fukui M et al.. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003;103:97–100.

  • 27.

    Maacke H, Hundertmark C, Miska S et al.. Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol 2002;128:219–222.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Xia Q, Kong XT, Zhang GA et al.. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 2005;330:526–532.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Kotera Y, Fontenot JD, Pecher G et al.. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856–2860.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Maacke H, Jost K, Opitz S et al.. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000;19:2791–2795.

  • 31.

    Hong SH, Misek DE, Wang H et al.. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004;64:5504–5510.

  • 32.

    Hong SH, Misek DE, Wang H et al.. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer. Biomarker Insights 2006;2:175–183.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Abu-Shakra M, Buskila D, Ehrenfeld M et al.. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60:433–441.

  • 34.

    Koopmann J, Fedarko NS, Jain A et al.. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487–491.

  • 35.

    Koopmann J, Buckhaults P, Brown DA et al.. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;10:2386–2392.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Koopmann J, Rosenzweig NW, Zhang Z et al.. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442–446.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Hwang TL, Liang Y, Chien KY et al.. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 2006;6:2259–2272.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Simeone DM, Ji B, Banerjee M et al.. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007;34:436–443.

  • 39.

    Koopmann J, Zhang Z, White N et al.. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860–868.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Gronborg M, Bunkenborg J, Kristiansen TZ et al.. Comprehensive proteomic analysis of human pancreatic juice. J Prot Res 2004;3:1042–1055.

  • 41.

    Chen R, Pan S, Yi EC et al.. Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006;6:3871–3879.

  • 42.

    Chen R, Pan S, Cooke K et al.. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007;34:70–79.

  • 43.

    Zhou L, Lu Z, Yang A et al.. Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics 2007;7:1345–1355.

  • 44.

    Rudd PM, Elliott T, Cresswell P et al.. Glycosylation and the immune system. Science 2001;291:2370–2376.

  • 45.

    Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005;83:429–439.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Dube DH, Bertozzi CR. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005;4:477–488.

  • 47.

    Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999;20:362–371.

  • 48.

    Semmes OJ, Malik G, Ward M. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. J Cell Biochem 2006;98:496–503.

  • 49.

    Kui Wong N, Easton RL, Panico M et al.. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 2003;278:28619–28634.

  • 50.

    Prakash S, Robbins PW. Glycotyping of prostate specific antigen. Glycobiology 2000;10:173–176.

  • 51.

    Block TM, Comunale MA, Lowman M et al.. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 2005;102:779–784.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Peracaula R, Tabares G, Royle L et al.. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003;13:457–470.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Peracaula R, Royle L, Tabares G et al.. Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states. Glycobiology 2003;13:227–244.

  • 54.

    Templin MF, Stoll D, Schwenk JM et al.. Protein microarrays: promising tools for proteomic research. Proteomics 2003;3:2155–2166.

  • 55.

    Pal M, Moffa A, Sreekumar A et al.. Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation. Anal Chem 2006;78:702–710.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Yan F, Sreekumar A, Laxman B et al.. Protein microarrays using liquid phase fractionation of cell lysates. Proteomics 2003;3:1228–1235.

  • 57.

    Orchekowski R, Hamelinck D, Li L et al.. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res 2005;65:11193–11202.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Madoz-Gurpide J, Wang H, Misek DE et al.. Protein based microarrays: a tool for probing the proteome of cancer cells and tissues. Proteomics 2001;1:1279–1287.

  • 59.

    Nam MJ, Madoz-Gurpide J, Wang H et al.. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003;3:2108–2115.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Bouwman K, Qiu J, Zhou H et al.. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003;3:2200–2207.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Qiu J, Madoz-Gurpide J, Misek DE et al.. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261–267.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Gao WM, Kuick R, Orchekowski RP et al.. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005;5:110.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Patwa TH, Zhao J, Anderson MA et al.. Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multilectin fluorescence detection. Anal Chem 2006;78:6411–6421.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Zhao J, Patwa TH, Qiu W et al.. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res 2007;6:1864–1874.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2007 by the National Comprehensive Cancer Network
Page Numbers:
8
Article Category:
Research Article
Received:
15 May 2007
Accepted:
13 Jun 2007
Print Publication Date:
01 Nov 2007
Online Publication Date:
Nov 2007
Keywords:
Biomarkers; proteomics; glycoproteins; autoantibodies

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1608 568 148
PDF Downloads 805 212 12
EPUB Downloads 0 0 0